Kimberly-Clark Corporation (NASDAQ:KMB) is preparing asset sales to address EU antitrust concerns surrounding its planned $40 billion acquisition of Kenvue, according to Reuters. The company is reportedly seeking to offer remedies that could secure European Commission approval by the September 29 deadline, avoiding a more extensive four-month investigation. Similar regulatory concerns have already emerged in Australia, where the deal received conditional approval after Kimberly-Clark agreed to divest Kenvue’s Carefree and Stayfree brands.
The transaction is strategically important because it would create a consumer-health and personal-care company with approximately $32 billion of annual revenue and $7 billion of adjusted EBITDA. Kimberly-Clark Corporation expects about $1.9 billion of annual cost synergies and $500 million of revenue synergies, although it expects to invest roughly $2.5 billion in cash to achieve the cost savings. Therefore, the scale of any EU divestitures will be critical to determining whether Kimberly-Clark can retain the expected economic benefits of the deal.
Regulatory Remedies Could Keep Kimberly-Clark’s $40B Kenvue Bet on Track
The strongest bullish argument is that Kimberly-Clark Corporation is actively working toward a regulatory solution rather than allowing the EU review to threaten the transaction. If the company can satisfy regulators through limited asset sales, it could preserve the majority of Kenvue’s revenue and earnings while moving ahead with the combination. The expected $1.9 billion in annual cost savings represents a substantial earnings opportunity relative to the combined company’s roughly $7 billion adjusted EBITDA target, giving Kimberly-Clark significant potential to improve margins and cash generation after integration.
The Australian precedent also suggests that targeted divestitures could be sufficient to resolve competition concerns without materially undermining the broader deal. Securing EU approval by September 29 would be particularly positive because it would remove a major source of uncertainty and allow Kimberly-Clark Corporation to focus on integration and synergy execution. With Kenvue adding major brands across consumer health and personal care, successful completion could also broaden Kimberly-Clark’s portfolio and reduce its reliance on its existing product categories.
A Prolonged EU Review Could Delay Kimberly-Clark’s Kenvue Payoff
The biggest risk is that the EU requires more substantial asset sales than Kimberly-Clark Corporation currently expects. Giving up attractive Kenvue brands or businesses in Europe could reduce the revenue and EBITDA acquired through the transaction, while Kimberly-Clark would still have to bear much of the financing, transaction, and integration burden. That could make the $40 billion purchase price less attractive on a risk-adjusted basis, particularly if the divested assets are among Kenvue’s stronger European businesses.
The timing also matters because Kimberly-Clark is pursuing the acquisition while its existing business is experiencing relatively modest growth. First-half 2026 organic sales increased only 1.2%, while the company subsequently lowered its full-year organic sales outlook. Kimberly-Clark also expects to spend $2.5 billion to realize the targeted synergies, meaning delays in regulatory approval could postpone the benefits while costs continue to accumulate. If the EU review extends into a lengthy investigation, the company could face higher execution risk and weaker near-term cash returns from the transaction.
Conclusion
The news is cautiously bullish for Kimberly-Clark Corporation because preparing asset sales increases the possibility of securing EU approval without a prolonged investigation. If the concessions are limited, Kimberly-Clark can retain most of Kenvue’s earnings while pursuing approximately $2.4 billion of combined cost and revenue synergies. Avoiding a lengthy regulatory process would also reduce uncertainty around one of the company’s largest strategic moves.
However, the upside is highly dependent on the scope of the remedies. Broad divestitures would directly reduce the assets and earnings Kimberly-Clark is paying $40 billion to acquire, while a prolonged review could delay the realization of synergies and increase transaction costs. Given the company’s modest underlying organic growth, the Kenvue deal needs to deliver meaningful earnings and cash-flow improvement to justify its scale. Overall, limited EU concessions would support the bull case, but aggressive remedies would significantly weaken the investment thesis.
READ NEXT: Oracle Adds $700 Million to the Cost of its AI Transformation and Nvidia’s Anthropic Investment: Securing AI Demand Amid Rising Competition
This article is originally published at Insider Monkey.
